Sharing knowledge to advance healthcare policies in Europe for people living with dementia and their carers: the ALCOVE project

Archives of Public Health

Christine Barr¹  Nathalie Riolacci-Dhoyen¹  Maggie Galbraith¹  Armelle Leperre-Desplanques¹  the ALCOVE GROUP² 

[1] Haute Autorité de Santé (HAS), Avenue du Stade de France, 93218, Saint-Denis La Plaine, France

[2] ALzheimer Cooperative Valuation in Europe Group, c/o Executive Agency for Health and Consumers, Health Unit, DRB A3/050, L-2920, Luxembourg, United Kingdom

关键词: Health care system;    Advanced declaration of will;    Diagnosis;    Prevalence;    Risk reduction;    Antipsychotics;    BPSD;    Public health;    Dementia;    Alzheimer’s disease and related dementia;   

Others  :  791056
DOI  :  10.1186/0778-7367-70-21

 received in 2011-12-22, accepted in 2012-04-15,  发布年份 2012

【 摘 要 】

Background

Alzheimer’s disease and other related dementias are public health priorities in the European Union due to their prevalence, cost and profound impact on society. Because of these pressing implications, the European Union decided to create a Joint Action to share knowledge about dementia and health policy in order to preserve the health, quality of life, autonomy and dignity of people living with dementia and their carers in Europe.

Methods

ALCOVE is a European Community-funded Joint Action coordinated by the HAS (French National Authority for Health) with a 24-month duration. The project’s life cycle has been divided into the following four steps: (1) collection of existing information, (2) analysis of existing information and making comparisons across Member States, (3) identifying Evidence, Needs, and Priorities, (4) drafting recommendations and disseminating them.

Results

19 countries are participating in the ALCOVE initiative. The project will publish its final findings in 2013. The project’s objectives, participants, method, on-going procedures and work plans are already available on the ALCOVE website:http://www.alcove-project.eu/ webcite. Preliminary results show that recommendations will need to focus on clinical and epidemiological data collection, diagnostic system assessment, outstanding approaches for treating behavioural disorders, limiting antipsychotic use, and competence assessment in this vulnerable population.

Conclusions

The European Member States involved are mobilized to share best health policy practices in order to tackle the challenge of dementia’s threat on European health and social systems and to improve the quality of life and care for individuals and their family carers.

【 授权许可】

   
2012 Barr et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Leon DA: Trends in European life expectancy: a salutary view. International Journal of Epidemiology 2011, 40:271-277.
• [2]Health at a Glance 2011: OECD Indicators http://singapour/intranet_has/index.php/site/content/download/2899/19382/file/OECD_indicators2011.pdf webcite
• [3]Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A: Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54(11 Suppl 5):S4-9.
• [4]Kiejna A, Frydecka D, Adamowski T, Bickel H, Reynish E, Prince M, Caracciolo B, Fratiglioni L, Georges J: Epidemiological studies of cognitive impairment and dementia across Eastern and Middle European countries (epidemiology of dementia in Eastern and Middle European Countries). Int J Geriatr Psychiatry 2011, 26(2):111-7.
• [5]Mathers C, Leonardi M: Global burden of dementia in the year 2000: summary of methods and data sources. Global Burden of Disease 2000.
• [6]Matias M: European Parliament resolution of 19 January 2011 on a European initiative on Alzheimer’s disease and related dementia and other dementias. http://www.europarl.europa.eu/sides/getDoc.do?pubRef=−//EP//TEXT+TA+P7-TA-2011-0016+0+DOC+XML+V0//EN webcite
• [7]Gustavsson A, Svensson M, Jacobi F, Allgulander C, et al.: Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011, 21(10):718-79.
• [8]Luengo-Fernandez R, Leal J, Gray AM: Cost of dementia in the pre-enlargement countries of the European Union. J Alzheimers Dis. 2011, 27(1):187-96.
• [9]Karlawish J: Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease. Neurology 2011, 77(15):1487-93.
• [10]Grand JH, Caspar S, Macdonald SW: Clinical features and multidisciplinary approaches to dementia care. J Multidiscip Healthc. 2011, 4:125-47.
• [11]O'Neil ME, Freeman M, Christensen V, Telerant R, Addleman A, Kansagara D: A Systematic Evidence Review of Non-pharmacological Interventions for Behavioral Symptoms of Dementia [Internet]. Washington (DC): Department of Veterans Affairshttp://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=vadementnopharm webcite
• [12]Ballard CG, Waite J, Birks J: Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003476.pub2/otherversions webcite
• [13]Banarjee S: The use of antipsychotic medication for people with dementia: A time for action. An independent report commissioned and funded by the Department of Health (England). http://www.dh.gov.uk webcite (Keyword Bannerjee) (Accessed January, 2010)
• [14]French Alzheimer Public Health Plan [ http://www.plan-alzheimer.gouv.fr/-44-measures-.html webcite]
• [15]Alzheimer Europe [ http://www.alzheimer-europe.org/ webcite]
• [16]Alert and mastering the antipsychotics’ iatrogenicity in Alzheimer Disease http://www.has-sante.fr/portail/jcms/c_1055540/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics webcite
• [17]Collaborative Method http://www.has-sante.fr/portail/jcms/c_1099538/syntheses-methodologiques webcite
• [18]Hausner L, Frölich L, Gardette V, Reynish E, Ousset PJ X, et al.: Regional Variation on the Presentation of Alzheimer’s Disease Patients in Memory Clinics within Europe: Data from the ICTUS study. Journal of Alzheimer’s Disease 2010, 155:155-165.
• [19]Ramakers I, Verhey F: Development of memory clinics in the Netherlands: 1998 to 2009. Aging & Mental Health 2011, 15(1):34-39.
• [20]Alzheimer’s disease and related conditions: Management of behavioural disorders 2009 http://www.has-sante.fr/portail/jcms/c_1055540/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics webcite
• [21]Petrovic M, Hurt C, Collins D, Burns A, Camus V, et al.: Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer’s dementia consortium (EADC) study. Acta Clin. Belg. 2007, 62:426-432.
• [22]Passmore MJ, Ho A, Gallagher R: Behavioural and psychological symptoms in moderate to severe Alzheimer’s disease; a palliative care approach emphasizing recognition of personhood and preservation of dignity. Journal of Alzheimer’s Disease 2012, 29:1-13.
• [23]Van De Ven G, Draskovic I, Adang E, Art R, Post A, Zuiderma S, et al.: Improving person-centred care in nursing homes through dementia –care mapping : design of a cluster randomised controlled trial. BMC Geriatrics 2012, 12:1. BioMed Central Full Text
• [24]Alzheimer’s disease and related conditions: Health monitoring for family carers - quick reference guide 2010 [ http://www.has-sante.fr/portail/jcms/c_1055540/alzheimer-s-disease-and-iatrogenicity-of-antipsychotics webcite]
• [25]Vernooij-Dassen M, Draskovic I, McCleery J, Downs M: Cognitive reframing for carers of people with dementia. Cochrane Database of Systematic Reviews 2011. Issue 11. Art. No.: CD005318
• [26]Dementia in Europe Yearbook 2011 http://www.Alzheimer Europe.org webcite
• [27]Howe EG: Ethical challenges when patients have dementia. J Clin Ethics 2011, 22(3):203-11.
• [28]de Boer ME, Hertogh CM, Dröes RM, Jonker C, Eefsting JA: Advance directives in dementia: issues of validity and effectiveness. Int Psychogeriatr 2010, 22(2):201-8. Epub 2009 Aug 10
• [29]European Dementia COnsensus Network: Competence Assessment in Dementia 2008. Ed. Stoppe
• [30]Gove D, Sparr S, Dos Santos Bernardo AM, Cosgrave MP, Jansen S, Martensson B, Pointon B, Tudose C, Holmerova I: Recommendations on end-of-life care for people with dementia. J Nutr Health Aging 2010, 14(2):136-9.
• [31]Wortmann M, Andrieu S, Mackell J, Knox S: Evolving attitudes to Alzheimer’s disease and related dementia among the general public and caregivers in Europe: findings from the IMPACT survey. J Nutr Health Aging 2010, 14(7):531-6.